Jacobio Pharmaceuticals’ Promising Cancer Drug Data

Jacobio Pharmaceuticals Group Co., Ltd. (HK:1167) has released an update.

Jacobio Pharmaceuticals has showcased promising pre-clinical data of its SHP2 inhibitor, JAB-3312, in combination with KRAS G12C inhibitor Glecirasib, demonstrating a significant anti-tumor effect in non-small cell lung cancer (NSCLC). The combination treatment has shown a 70.6% objective response rate in NSCLC patients and has entered a phase III trial in China. The company’s recent presentation at the Fifth RAS Initiative Symposium highlights its commitment to leading-edge oncology drug development.

For further insights into HK:1167 stock, check out TipRanks’ Stock Analysis page.